Abstract: There is provided compounds of formula I, wherein the dotted line, X1, X2, X3, A, Y1, Y2, Y3, Y4, Z1, Z2, R2 and R3 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful as selective agonists of the AT2 receptor, and thus, in particular, in the treatment of inter alia gastrointestinal conditions, such as dyspepsia, IBS and MOF, and cardiovascular disorders.

Abstract: Compounds of the formula I: wherein R1, R2, X and N are as defined in the specification; E is N, CH; A? and A? are terminal groups as defined in the specification. The compounds have utility as HIV-1 protease inhibitors.

Abstract: There is provided compounds of formula I, wherein the dotted line, X1, X2, X3, A, Y1, Y2, Y3, Y4, Z1, Z2, R2 and R3 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful as selective agonists of the AT2 receptor, and thus, in particular, in the treatment of inter alia gastrointestinal conditions, such as dyspepsia, IBS and MOF, and cardiovascular disorders.

Abstract: There is provided a compound of formula I, wherein R1a, R1b, X, Y1, Y2, Y3, Y4, Z1, Z2, R2 and R3 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful as selective agonists of the AT2 receptor, and thus, in particular, in the treatment of inter alia gastrointestinal conditions, such as dyspepsia, IBS and MOF, and cardiovascular disorders.

Abstract: There is provided compounds of formula I, wherein A, X1, X2, X3, X4, Y1, Y2, Y3, Y4, Z1, Z2, R4 and R5 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful as selective agonists of the AT2 receptor, and thus, in particular, in the treatment of inter alia gastrointestinal conditions, such as dyspepsia, IBS and MOF, and cardiovascular disorders.

Abstract: Compounds of the formula I: wherein R1, R2, X and N are as defined in the specification; E is N, CH; A? and A? are terminal groups as defined in the specification. The compounds have utility as HIV-1 protease inhibitors.

Abstract: There is provided a use of a compound of formula (I), wherein R1, R2, R3 and R4 have meanings given in the description, and pharmaceutically-acceptable salts thereof, for the manufacture of a medicament for the treatment of a disease in which inhibition of the activity of a lipoxygenase (e.g. 15-lipoxygenase) is desired and/or required, and particularly in the treatment of inflammation.

Abstract: There is provided a compound of formula (I), wherein R1, R2, R3, X and Y have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a lipoxygenase (e.g. 15-lipoxygenase) is desired and/or required, and particularly in the treatment of inflammation.

Abstract: The invention provides novel compounds or the formula II: wherein R1, R2, R3 and R4 are independently hydrogen of a group that liberates the free amine in vivo, for example —CO-alkyl, preferably —CO—C1-C3 alkyl or pivalate; or —COhaloalkyl, preferably —CO—C1-C3 haloalkyl, most preferably —CO—C1-C3 chloroalkyl; wherein W is: and @ denotes the points of attachment and wherein the ester can be located in either direction; wherein n and m are independently 0-5; wherein one but not both or X and Y can be nitrogen, or X is C-A and/or Y is C—B; wherein A and B are independently selected from hydrogen, alkyl optionally substituted with a halogen, an electron donor group such as amino, alkylamino, dialkylamino or hydroxy, or an electron acceptor group such as nitro, cyano. trihaloalkyl or amido, alkoxy or halogen; and pharmacologically acceptable salts thereof.

Abstract: Compounds of the formula I: 1

Abstract: The present invention is draw to microwave heating of a transition metal-catalysed organic reaction, in which a catalyst complex between a transition metal and an auxiliary ligand or ligands, the ligand being asymmetric or symmetric, monodentate or bidentate, results in highly chemoselective, regioselective, and stereoselective allylic substitution reactions. Molybdenum or palladium complexes form suitable catalytic systems with a plethora of ligands in a variety of solvents for such microwave facilitated nucleophilic substitution reactions.

Abstract: The present invention is drawn to a method of performing a one-pot organic reactions including carbon monoxide as reactant, without the use of an external CO gas source, wherein a reaction mixture containing a solid or liquid CO releasing compound, a non-metal substrate and a metal catalyst is exposed to an energy source to release carbon monoxide from the CO releasing compound and wherein carbon atoms of the released carbon monoxide form a bond with the non-metal substrate compound. The present invention is further drawn to a method of preparing chemical libraries and a kit for organic reactions.

Abstract: Organic reactions catalyzed by palladium, except Pd/C, are conducted with heating by microwave energy. The preferred inorganic reactions involved are coupling reactions in which a new carbon-carbon bond is formed. Preferred reactions are the Heck, Stille and Suzuki reaction. The method provides high yields in very short reaction times.

Abstract: An opening arrangement on a packing container of the type which comprises a pouring opening 6 formed in the upper side of the container. The opening arrangement comprises a cover strip 8 and a pouring edge strip 7 arranged between the cover strip 8 and the packing container. To make possible the reclosure of the pouring opening 6 the cover strip 8 is provided with a gripping strip 9' sealed to its underside which preferably has a free gripping edge 9" facilitating the hooking of the cover strip 8 to the pouring tab 7.